Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Purchase, Stockpile Enough Inavir for 3.81 Million People, Avigan for 1.91 Million People
March 23, 2018
- MHLW Orders Label Revisions for Samsca Acute Liver Failure Added to Significant ADR List
March 22, 2018
- Healthcare Experts at Odds over Nonprescription Switches of 3 PPIs
March 20, 2018
- Price Adjustments Based on Cost-Effective Assessments “Impossible”: Prof. Sakamaki
March 20, 2018
- MHLW to Discuss Creation of Post-Launch Premium for Add’l Indications: Official
March 20, 2018
- MHLW Health Policy Chief Questions Volume-Focused Sales Strategies, Urges Drug Makers to Shift to Healthy Lifespan Extension
March 19, 2018
- Lift Ban on Coadministration of Adrenalin Medications with Alpha-blocking Antipsychotic Drugs: MHLW Panel
March 19, 2018
- PMDA Estimates MID-NET Will Be Used for PMS for 18 Products Annually
March 16, 2018
- 3rd Batch of Sakigake Drugs to Be Announced Soon: MHLW Official
March 15, 2018
- MHLW Issues Safety Information with Special Feature on MID-NET Expected to Begin Full-Scale Operation on April 1
March 15, 2018
- PMDA’s Review Segment to Post Loss of around 500 Million Yen in FY2017; Ordinary Loss to Be Covered by Reserve Fund
March 14, 2018
- PMDA to Establish “Regulatory Science Center” in April to Deal with Advanced Science and Technology
March 14, 2018
- MHLW to Relax Regulatory Procedures to Prevent Discrepancies between Approved and Actual Manufacturing Practices
March 13, 2018
- Lexicon: G1/G2 Rule
March 9, 2018
- AMED Taking Applications for FY2018 CiCLE Grant Program, Will Make Final Selection by Early October
March 9, 2018
- Funding Disclosure Methods that Prohibit Printing Will Not Be Acceptable: MHLW Notifications on Clinical Research Law
March 9, 2018
- MHLW Proposes Working Group Discussions before Another Round of CEA Analyses for 7 Products: Chuikyo
March 8, 2018
- Kadcyla’s Premium Portion Cut by 90% on CEA, 1 Device Gets Upward Adjustment: Chuikyo
March 8, 2018
- Xofluza Subject to April Price Revision, but Will Maintain Full Price: MHLW Official
March 8, 2018
- Why Did Xarelto, Eliquis Lose PMP Eligibility?
March 7, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…